DMYD-B.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:29):

Stats
今日成交量	251 085
平均成交量	267 441
市值	1.10B
EPS	SEK0 ( 2023-10-11 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-8.75
ATR14	SEK0.0680 (0.57%)

音量相关性

長: 0.06 (neutral)

短: 0.29 (neutral)

Signal:(45.548) Neutral

Diamyd Medical AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Diamyd Medical AB (publ) 相关性 - 货币/商品

-0.44
( neutral )

-0.26
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.17
( neutral )

-0.03
( neutral )

Diamyd Medical AB (publ) 财务报表

Annual	2023
营收:	SEK546 000
毛利润:	SEK-3.09M (-565.57 %)
EPS:	SEK-1.480

FY	2023
营收:	SEK546 000
毛利润:	SEK-3.09M (-565.57 %)
EPS:	SEK-1.480

FY	2022
营收:	SEK454 000
毛利润:	SEK-3.95M (-869.82 %)
EPS:	SEK-1.130

FY	2021
营收:	SEK253 000
毛利润:	SEK-2.25M (-888.54 %)
EPS:	SEK0.868

Financial Reports:

No articles found.

Diamyd Medical AB (publ)

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.